Resverlogix Corp
Resverlogix Corp, based in Calgary, AB, is a late-stage clinical biotechnology company dedicated to enhancing the lives of patients with chronic illnesses through innovative epigenetic therapeutics. Its lead product, Apabetalone, is currently undergoing late-stage clinical evaluation for high-risk cardiovascular disease and post COVID-19 conditions.
Founded in 2001 by Donald McCaffrey and Norman Wong, Resverlogix focuses on developing value-based health solutions and has received Breakthrough Therapy designation from the US FDA for Apabetalone, positioning itself as a global leader in modern medicine. The company's BETonMACE clinical trial is recognized as the most advanced epigenetic drug trial outside of oncology.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2024. All rights reserved.
Partial Data by Foursquare.